ENDRA Life Sciences Inc. has announced its financial results for the first quarter of 2025, reporting a significant reduction in cash burn and operating expenses. The company's cash burn decreased to $1.2 million, compared to $1.7 million in the first quarter of 2024. Operating expenses saw a nearly 50% decrease, falling to $1.5 million from $2.8 million in the same period last year, reflecting aggressive cost-cutting measures. Net loss for the first quarter of 2025 was $1.0 million, down from $2.8 million in the year-ago period. As of March 31, 2025, ENDRA had $2.1 million in cash and cash equivalents. Following the quarter-end, the company raised an additional $0.8 million under its 2024 At-the-Market facility, bringing the total to $2.5 million as of April 30, 2025. ENDRA has also provided a business update, highlighting a strategic pivot to focus on metabolic disease management. The company is developing a low-cost, point-of-care diagnostic device for steatotic liver disease, akin to a "blood pressure cuff" for the liver. Additionally, ENDRA plans to expand the applications of its TAEUS platform beyond liver fat measurement to include temperature monitoring during ablation therapies and vascular and tissue perfusion imaging. During the first quarter, ENDRA was granted two new patents in China, contributing to a total of 84 patents in its intellectual property portfolio.